The trial's primary goal is to assess the efficacy, safety and tolerability of daily oral doses of SCI-110 in adults aged 18 ...

King of Prussia’s CluePoints unveiled its latest innovation, reports Timothy Alexander for MSN. Medical & Safety Review (MSR) ...

FDA confirms that SciSparc’s study may proceedonly a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ...

Clinical trial recruitment stands at the forefront of drug and medical device development for companies, yet it often ...

BUFFALO, NY / ACCESSWIRE / September 27, 2024 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, ...

In September 2024, the U.S. Food and Drug Administration (FDA) issued three guidance documents to support different clinical ...

Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

New 56-week data from an interim analysis of the phase III ARCADIA long-term extension study will be presented, with nemolizumab demonstrating a ...